Dehydroepiandrosterone Sulfate
Label Mnemonic: DHEAS
Epic Lab Code: LAB524
Downtime Form: A-1a General Laboratory Requisition
Chemistry
6240 RCP
356-3527
Specimen(s):
Plasma
Collection Medium:
Plasma Separator Tube 4.5 mL
Alternate Collection Media:
Call laboratory for additional acceptable specimen collection containers.
Minimum:
3 mL whole blood in light green top tube or TWO Microtainer® devices.
Testing Schedule:
24 hrs/day, 7 days a week, including holidays.
Turn Around Time:
1 hour (upon receipt in laboratory)
Reference Range:
  Age Male μg/dL Female μg/dL 0-6 days 108-607 108-607 7-30 days 32-431 32-431 1-5 months 3-124 3-124 6-35 months 0-33 0-29 3-6 years 0-44 0-47 7-9 years 5-115 5-94 10-14 years 22-332 22-255 15-19 years 88-483 63-373 20-29 years 280-640 65-380 30-39 years 120-520 45-270 40-49 years 95-530 32-240 50-59 years 70-310 26-200 60-69 years 42-290 13-130 70 years and older 28-175 10-90 Tanner Stage I 7-209 7-126 Tanner Stage II 28-260 13-241 Tanner Stage III 39-390 32-446 Tanner Stage IV & V 81-488 65-371
Test Limitations:
Dehydroepiandrosterone sulfate (DHEA-S) is a weak androgen secreted primarily by the "zona reticularis" of the adrenal cortex. Secretion is controlled by ACTH and other pituitary factors. Physiologically, DHEA-S has many roles, including the development of pubic and axillary hair, the development and maintenance of immunocompetence, and as a possible tumor marker. Serum levels of DHEA-S are one thousand times greater than DHEA. DHEA levels show diurnal variation while DHEA-S does not. Levels change slowly due to slow metabolism and low renal clearance. Clinical indications for DHEA-S include work-up of: Hirsutism and amenorrhea (the most common sign of increased adrenal androgen production by women) Polycystic ovarian syndrome, where high DHEA-S levels are often encountered. However, levels greater than 700-800 μg/dL in women may be suggestive of a hormone secreting adrenal tumor. Congenital adrenal hyperplasia The assay is unaffected by icterus (bilirubin less than 13 mg/dL), hemolysis (Hb less than 560 mg/dL), lipemia (Intralipid less than 2000 mg/dL) and biotin less than 30 ng/mL (criterion: recovery within plus or minus 10% of initial value). In patients receiving therapy with high biotin doses (i.e. greater than 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No interference was observed from rheumatoid factors up to a concentration of 600 U/mL.
Methodology:
Electrochemiluminescence Immunoassay
CPT Code:
82627